Cargando…

Polyoxometalates Impact as Anticancer Agents

Polyoxometalates (POMs) are oxoanions of transition metal ions, such as V, Mo, W, Nb, and Pd, forming a variety of structures with a wide range of applications. Herein, we analyzed recent studies on the effects of polyoxometalates as anticancer agents, particularly their effects on the cell cycle. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho, Fátima, Aureliano, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003337/
https://www.ncbi.nlm.nih.gov/pubmed/36902473
http://dx.doi.org/10.3390/ijms24055043
_version_ 1784904582742147072
author Carvalho, Fátima
Aureliano, Manuel
author_facet Carvalho, Fátima
Aureliano, Manuel
author_sort Carvalho, Fátima
collection PubMed
description Polyoxometalates (POMs) are oxoanions of transition metal ions, such as V, Mo, W, Nb, and Pd, forming a variety of structures with a wide range of applications. Herein, we analyzed recent studies on the effects of polyoxometalates as anticancer agents, particularly their effects on the cell cycle. To this end, a literature search was carried out between March and June 2022, using the keywords “polyoxometalates” and “cell cycle”. The effects of POMs on selected cell lines can be diverse, such as their effects in the cell cycle, protein expression, mitochondrial effects, reactive oxygen species (ROS) production, cell death and cell viability. The present study focused on cell viability and cell cycle arrest. Cell viability was analyzed by dividing the POMs into sections according to the constituent compound, namely polyoxovanadates (POVs), polyoxomolybdates (POMos), polyoxopaladates (POPds) and polyoxotungstates (POTs). When comparing and sorting the IC(50) values in ascending order, we obtained first POVs, then POTs, POPds and, finally, POMos. When comparing clinically approved drugs and POMs, better results of POMs in relation to drugs were observed in many cases, since the dose required to have an inhibitory concentration of 50% is 2 to 200 times less, depending on the POMs, highlighting that these compounds could become in the future an alternative to existing drugs in cancer therapy.
format Online
Article
Text
id pubmed-10003337
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100033372023-03-11 Polyoxometalates Impact as Anticancer Agents Carvalho, Fátima Aureliano, Manuel Int J Mol Sci Review Polyoxometalates (POMs) are oxoanions of transition metal ions, such as V, Mo, W, Nb, and Pd, forming a variety of structures with a wide range of applications. Herein, we analyzed recent studies on the effects of polyoxometalates as anticancer agents, particularly their effects on the cell cycle. To this end, a literature search was carried out between March and June 2022, using the keywords “polyoxometalates” and “cell cycle”. The effects of POMs on selected cell lines can be diverse, such as their effects in the cell cycle, protein expression, mitochondrial effects, reactive oxygen species (ROS) production, cell death and cell viability. The present study focused on cell viability and cell cycle arrest. Cell viability was analyzed by dividing the POMs into sections according to the constituent compound, namely polyoxovanadates (POVs), polyoxomolybdates (POMos), polyoxopaladates (POPds) and polyoxotungstates (POTs). When comparing and sorting the IC(50) values in ascending order, we obtained first POVs, then POTs, POPds and, finally, POMos. When comparing clinically approved drugs and POMs, better results of POMs in relation to drugs were observed in many cases, since the dose required to have an inhibitory concentration of 50% is 2 to 200 times less, depending on the POMs, highlighting that these compounds could become in the future an alternative to existing drugs in cancer therapy. MDPI 2023-03-06 /pmc/articles/PMC10003337/ /pubmed/36902473 http://dx.doi.org/10.3390/ijms24055043 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Carvalho, Fátima
Aureliano, Manuel
Polyoxometalates Impact as Anticancer Agents
title Polyoxometalates Impact as Anticancer Agents
title_full Polyoxometalates Impact as Anticancer Agents
title_fullStr Polyoxometalates Impact as Anticancer Agents
title_full_unstemmed Polyoxometalates Impact as Anticancer Agents
title_short Polyoxometalates Impact as Anticancer Agents
title_sort polyoxometalates impact as anticancer agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003337/
https://www.ncbi.nlm.nih.gov/pubmed/36902473
http://dx.doi.org/10.3390/ijms24055043
work_keys_str_mv AT carvalhofatima polyoxometalatesimpactasanticanceragents
AT aurelianomanuel polyoxometalatesimpactasanticanceragents